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The Clinical Usefulness of Gamma-Seminoprotein as a Prognostic Factor at Relapse of The Prostage Cancer
KAZUAKI IWABUCHI (Department of Urology Saitama Medical School, Moroyama, Iruma-gun, Saitama 350-0495, Japan) 
In the present report, it was clarified whether or not cancer markers, namely prostate specific antigen (PSA)
and gamma-seminoprotein (γ- Sm ), could predict the prognosis for recurrent prostate cancer. Of 139 patients 
who were diagnosed with prostate cancer over a ten year period between January 1989 and December 1998, data 
obtained from 43 patients with recurrent prostate cancer were statistically analyzed. Levels of PSA andγ- Sm were 
measured using the enzyme immunoassay (EIA) method. These patients with relapse prostate cancer were divided 
into two groups with respect to the median of each marker. Differences in survival periods following relapse 
were compared by the Kaplan-Meier method. Although PSA andγ- Sm/PSA ratio did not have any statistically 
significant effect on survival, the 50% survival for the lowγ- Sm group (2 years and 7 months) was significantly 
longer than that for the highγ- Sm group (1 year and 2 months). Also, theγ- Sm/PSA ratio at the time of relapse 
was significantly lower than that at the initial treatment. As a result, even though PSA was totally ineffective in 
predicting prognosis following relapse,γ- Sm was shown to be a useful prognostic factor following relapse.
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Free/Total PSA ratio）およびγ- Smが予後推定因子と
して有用であることを報告した．
　しかし，再燃前立腺癌については Scherらの指摘




























































　再燃後観察期間は 1－ 345週，中央値 74週（28週，
115週）であった．




























γ- Sm：γ- Sm/PSA比は初期治療前が＋ 0.089，再燃時
が＋ 0.269であった（Table 2）．
2. 再燃後生存期間への影響
　全症例 43例における PSAおよびγ - Sm/PSA比
においては有意な生存への影響を認めなかった
（Fig. 1，Fig. 2）．
　γ - Smでは低値群の再燃後 50 %生存期間が 2年
7ヶ月，高値群は 1年 2ヶ月と低値群が有意に良好で





Table 2. Correlation of PSA ,γ-Sm and γ-Sm/PSA ratio 
(Spearman rank correlation coefficient)
Table 1. Median (minimum-maximum) value of cancer 





















Fig . 1.  Kaplan-Meier survival curve in PSA. (log-rank test)
Fig. 2. Kaplan-Meier survival curve in γ-Sm/PSA ratio. 
(log-rank test)
Table 4. Background of age in all patient (n＝43)
＊: median (minimum-maximum) value
※ Wilcoxon rank-sum test        
※※ Contingency table (χ2 test)
Fig. 4.  Kaplan-Meier survival curve in age. (log-rank test)
Table 3. Background of γ-Sm in all patient (n＝43)
＊: median (minimum-maximum) value
※ Wilcoxon rank-sum test        
※※ Contingency table (χ2 test)














　黒川らは PSA ratio は治療による影響を受けず
変化しないと報告している12)．しかし，今回の研
究では再燃時にγ - Sm/PSA 比は有意に低下した
（p ＜ 0.05）．これは Stein らによる再燃時の PSA 
ratio 低下の報告と合致したものである13)．なお，
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